Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK

SpringWorks Therapeutics Inc (NASDAQ:SWTX) has entered into an expanded global, non-exclusive license and collaboration agreement with GSK plc (NYSE:GSK) for SpringWorks’ nirogacestat with…
byVandana Singh
September 7, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • SpringWorks Therapeutics Inc (NASDAQ:SWTX) has entered into an expanded global, non-exclusive license and collaboration agreement with GSK plc (NYSE:GSK) for SpringWorks’ nirogacestat with GSK’s Blenrep.
  • SpringWorks will receive a $75 million equity investment from GSK, and it is eligible to receive up to $550 million in milestone payments.
  • In May, SpringWorks announced positive topline results from the DeFi Phase 3 trial evaluating nirogacestat in adult patients with progressing desmoid tumors.
  • SpringWorks and GSK first entered into a trial collaboration and supply agreement in June 2019, later amended in October 2021, to cover the initial clinical development of nirogacestat in combination with Blenrep for relapsed or refractory multiple myeloma. 
  • The new agreement expands the original collaboration to include the combination of nirogacestat and Blenrep in earlier lines of treatment, including newly diagnosed multiple myeloma. 
  • Price Action: SWTX shares are up 5.54% at $27.45, and GSK stock is down 0.10% at $31.44 on the last check Wednesday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Why Palisade Bio Stock Is Soaring Today

By Erica Kollmann
April 16, 11:47 AM
Palisade Bio shares are trading higher Tuesday after the company announced the completion of its analysis evaluating ex-vivo bioactivation of PALI-2108. Palisade Bio said the findings demonstrated PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with ulcerative colitis (UC). The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time.

PALI

Read More

Lanvin Group and Primavera Capital Acquisition Corporation Announce Shareholder Approval of Business Combination; Trade Debut Expected on NYSE on December 15 Under Ticker “LANV”

By Charles Gross
December 12, 7:04 AM
Lanvin Group (the "Group"), a global luxury fashion group, and Primavera Capital Acquisition Corporation (NYSE: PV) ("PCAC"), today announced that PCAC shareholders approved the previously announced business combination with the Group at an extraordinary general meeting of shareholders on December 9, 2022. Shareholders of the Grou

PV